Activity, Motor Control & Coordination
Pain - Thermal Allodynia / Hyperalgesia
Pain - Spontaneous Pain - Postural Deficit
Pain - Mechanical Allodynia / Hyperalgesia
Anxiety & Depression Disorder
Learning/Memory - Attention - Addiction
Physiology & Respiratory Research
Metabolism - Food & Drink Intake
Pain
Central Nervous System (CNS)
Neurodegeneration
Sensory system
Motor control
Mood Disorders
Other disorders
Muscular system
Joints
Metabolism
Cross-disciplinary subjects
Preclinical studies and opioids: role in crisis management in the United States Authors
D Richards, JR Gever, AP Ford, SJ Fountain
Lab
Biomedical Research Centre, School of Biological Sciences, University of East Anglia, Norwich, UK
Journal
British Journal of Pharmacology
Abstract
The P2X3 receptor is an ATP_gated ion channel expressed by sensory afferent neurons and is used as a target to treat chronic sensitisation conditions. The first_in_class, selective P2X3 and P2X2/3 receptor antagonist, the diaminopyrimidine MK_7264 (gefapixant), has progressed to Phase III trials for refractory or unexplained chronic cough. We used patch clamp to elucidate the pharmacology and kinetics of MK_7264 and rat models of hypersensitivity and hyperalgesia to test its efficacy on these conditions.
BIOSEB Instruments Used:
Von Frey Filaments (Bio-VF-M)
